BioNTech / Pfizer and AstraZeneca Offer Fairly High Levels of Vaccination Against Indian Virus Variant

According to a study from Great Britain, the corona vaccines from BioNTech / Pfizer and AstraZeneca offer quite a high level of protection against illness with the virus variant B.1.617.2, which first appeared in India.

The vaccine from Pfizer / Biontech protects against disease caused by B.1.617.2. Two weeks after the second dose with 88 percent effectiveness, compared with 93 percent for the British variant.

At Astrazeneca, the effect against disease caused by B.1.617.2 is 60 percent, compared to 66 percent with B.1.1.7. According to the information, both vaccines had a 33 percent effectiveness with B.1.617.2 three weeks after the first vaccination, while it was around 50 percent for the British variant at the time.

The study was conducted between April 4 and May 16 and covered all age groups. The Indian variant is considered particularly contagious and has made a significant contribution to the fact that the number of infections in India has exploded in recent months. In the UK, as of May 19, more than 3,400 cases of the variant have been confirmed. Because of the spread of the variant, Great Britain will be classified by the German federal government as a virus variant area from Sunday.

The British scientific advisory board Sage recently wrote that it was “realistic” that the Indian variant could be up to 50 percent more contagious than variant B.1.1.7, which is already considered very contagious.

While BioNTech shares rose 0.92 percent to $ 197.50 on the NASDAQ, shares of Pfizer on the NYSE rose 0.15 percent to $ 40.01.